10 Best Low Priced Biotech Stocks to Buy Now

4. Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Stock Price: $5.98

Number of Hedge Fund Holders: 40

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is the fourth-best low-priced biotech stock to buy now. The company discovers, develops, and delivers medicines to treat metabolic diseases. Its product portfolio includes the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

On May 2, Leerink Partners analyst Joseph Schwartz reiterated their bullish stance on Amicus Therapeutics, Inc. (NASDAQ:FOLD), giving a Buy rating due to its growth potential and strategic positioning. The company recently announced a licensing agreement for DMX-200 to treat focal segmental glomerulosclerosis (FSGS), which has no FDA-approved therapies.

The analyst is bullish on the stock because of this strategic effort to capitalize on the regulatory advancements in the FSGS space. Since there are around 15,000 to 30,000 patients suffering from the condition in the United States, this move presents a significant market opportunity for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

The agreement’s financial terms include a $30 million upfront payment and up to $560 million in milestone payments, highlighting a well-structured yield with the potential to produce considerable returns, supporting the buy rating. Analysts are thus bullish on the stock, and its median price target of $5.98 implies an upside of 167.56% from current levels.